Nanomerics is pleased to announce the strengthening of its Scientific Advisory Board with the appointment of Professor Martin Koltzenburg.
Professor Koltzenburg’s appointment will support the clinical development of Nanomerics' lead product NM0127, a novel pain therapeutic based on an endogenous peptide.
Professor Koltzenburg is a leading expert in the neurophyisology of pain, with over 100 peer reviewed original articles in the clinical and basic sciences. He is Head of the Department of Clinical Neurophysiology at The National Hospital for Neurology and Neurosurgery at Queen Square, London, and has been awarded several scientific prizes including the Research Prize of the International Association for the Study of Pain, and the Patrick Wall Medal of the British Pain Society. Prof Koltzenburg’s experience in the clinical evaluation of therapies for chronic and neuropathic pain will be of particular benefit in guiding the upcoming clinical development of NM0127.